Consider WELTRUZA for adults with schizophrenia, such as those who:
Are currently prescribed oral olanzapine and looking for a long-acting treatment1
Have previously tolerated olanzapine1
Have difficulty maintaining a daily regimen2
Patient case example for WELTRUZA
Meet Emily
Emily is currently being treated with oral olanzapine. She has been struggling with symptoms, including delusions and agitated moods. When she spoke with her HCP, she wondered whether this was related to missed doses. Her symptoms have made it difficult to complete daily tasks and function independently, which led to recent acute hospitalization. She is interested in discussing another treatment option with her HCP that could provide symptom improvement.
Current treatment status:
Emily frequently misses daily oral olanzapine doses
Recently hospitalized due to worsening positive symptoms
She may benefit from a long-acting option that does not require daily use
Learn how WELTRUZA may help your patients like Emily.
In a companion study,
93% of patients
reported being satisfied with WELTRUZA3*
Study design: A one-time prospective, cross-sectional, observational survey of 70 patients and 35 HCPs participating in the SOLARIS trial. The survey collected patient-reported outcomes data and assessed attitudes toward and experiences with long-acting injectable treatment attributes, delivery of care, and treatment satisfaction.3
*Based on initiation regimen, dosing schedule, and needle
length.3
up next
Phase 3 trial
The SOLARIS study evaluated the efficacy of WELTRUZA on symptom improvement (PANSS) and personal and social performance (PSP).
SOLARIS STUDY DESIGNReferences: 1. WELTRUZA™ (olanzapine) extended-release injectable suspension Current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Zacker C, Puckett JT, Kamal-Bahl S. Real-world adherence and discontinuation of oral antipsychotics and associated factors in a national sample of US Medicare beneficiaries with
schizophrenia. Clinicoecon Outcomes Res. 2024;16:567-579. 3. Cutler AJ, Gonzalez A, Suett M, et al. Patient and healthcare professional attitudes and trial experiences with a subcutaneous long-acting injectable olanzapine (TV-44749) for the treatment of schizophrenia. Presented at: Schizophrenia International Research Society (SIRS) 2025 Annual Congress; March 29-April 2, 2025; Chicago, IL.
